alexa Pancreatic Cancer: Specific Problems of Genetic Profili
ISSN: 2165-7092

Pancreatic Disorders & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

Pancreatic Cancer: Specific Problems of Genetic Profiling

Beatrice Mohelnikova-Duchonova1,2*
1Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic
2Department of Oncology, Palacky University Medical School and Teaching Hospital in Olomouc, Czech Republic
Corresponding Author : Beatrice Mohelnikova-Duchonova
Department of Oncology
Palacky University Medical School and Teaching Hospital in Olomouc
Czech Republic
E-mail: [email protected]
Received March 26, 2013; Accepted April 08, 2013; Published April 10, 2013
Citation: Mohelnikova-Duchonova B (2013) Pancreatic Cancer: Specific Problems of Genetic Profiling. Pancreatic Dis Ther 3:111. doi:10.4172/2165-7092.1000111
Copyright: © 2013 Mohelnikova-Duchonova B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Pancreatic cancer is the fourth leading cause of cancer death in the United States and Europe. The prognosis of patients with pancreatic cancer remains extremely poor, with five-year survival being less than 5%. The most serious problems of pancreatic cancer are: i/ late diagnosis due to absence tests allowing early detection of the tumor, ii/ poor prognosis, which does not correlate with classic clinical factors and iii/ very limited efficacy of chemotherapy, which usually works in other tumor types. From existing data, it is evident that molecular factors such as genetic profiles, proteins expression and their activity exist and need to be validated and additional ones discovered for use in more precise division of patients into prognostic subgroups as well as it is imperative to identify subgroups of patients who may benefit from specific biological agents and “tailor” therapy to their “tumor profile”.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version